New Method Could Help Stem Cell-Derived Insulin Cells Work Better After Transplant

One promising approach to treating type 1 diabetes involves growing insulin-producing beta cells from stem cells in the laboratory. These stem cell-derived beta cells could theoretically replace the cells that the immune system attacks in type 1 diabetes. However, scientists have struggled to make these lab-grown cells behave exactly like the natural insulin-producing cells in the human body—particularly in their ability to sense glucose and release the right amount of insulin at the right time.

Researchers know that immune cells called macrophages play an important role in how natural insulin-producing cells develop in the body. Building on this insight, a team wondered whether adding macrophages during the lab growth process could help stem cell-derived insulin cells mature and function better.

The researchers tested three types of macrophages: unpolarized macrophages, inflammatory macrophages, and regenerative macrophages. They coaggregated (grew together) each type with developing insulin cells during a critical stage of development.

When insulin cells were grown alongside regenerative macrophages, they showed notable improvements. The cells expressed more maturity markers—molecular signs that the cells were developing correctly. They also released insulin in response to glucose at higher levels, and their overall metabolic activity increased. In contrast, unpolarized and inflammatory macrophages did not produce these benefits.

These findings suggested that not all immune cells have the same effect; the specific type of macrophage matters significantly for supporting insulin cell development.

The researchers then transplanted the lab-grown insulin cells into mice with diabetes. When the insulin cells were transplanted alongside regenerative macrophages, the mice's blood sugar levels normalized significantly faster compared to mice receiving insulin cells alone. This suggests the benefits seen in the lab translated into improved function after transplant.

While these results are encouraging, this work represents an advance in the laboratory development of stem cell-based treatments. Clinical trials of stem cell-derived insulin cells in humans are already underway, and findings like these may help optimize those treatments in the future.

Source: Science advances. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.